מדינה: שווייץ
שפה: איטלקית
מקור: Swissmedic (Swiss Agency for Therapeutic Products)
proteinum L1 papillomaviri dell'essere umano di tipo 6, proteinum L1 papillomaviri del tipo umano 11, proteinum L1 papillomaviri dell'essere umano di tipo 16, proteinum L1 papillomaviri tipo umano 18, proteinum L1 papillomaviri tipo umano 31, proteinum L1 papillomaviri tipo umano 33, proteinum L1 papillomaviri tipo umano 45, proteinum L1 papillomaviri umano di tipo 52, proteinum L1 papillomaviri tipo umano 58
MSD Merck Sharp & Dohme AG
J07BM03
proteinum L1 papillomaviri of the human type 6, proteinum L1 papillomaviri of the human type 11, proteinum L1 papillomaviri of the human type 16, proteinum L1 papillomaviri human type 18, proteinum L1 papillomaviri human type 31, proteinum L1 papillomaviri human type 33, proteinum L1 papillomaviri human type 45, proteinum L1 papillomaviri human type 52, proteinum L1 papillomaviri human type 58
Sospensione iniettabile in Flaconcino
proteinum L1 papillomaviri humani typus 6 30 µg, proteinum L1 papillomaviri humani typus 11 40 µg, proteinum L1 papillomaviri humani typus 16 60 µg, proteinum L1 papillomaviri humani typus 18 40 µg, proteinum L1 papillomaviri humani typus 31 20 µg, proteinum L1 papillomaviri humani typus 33 20 µg, proteinum L1 papillomaviri humani typus 45 20 µg, proteinum L1 papillomaviri humani typus 52 20 µg, proteinum L1 papillomaviri humani typus 58 20 µg, aluminium ut aluminii hydroxyphosphas sulfas amorphus, natrii chloridum, histidinum, polysorbatum 80, natrii boras, aqua ad iniectabile ad suspensionem pro 0.5 ml corresp. natrium 3.78 mg.
B
Vaccini
Papillomavirus Umano Vaccino (Tipi 6, 11, 16, 18, 31, 33, 45, 52, 58)
zugelassen
1970-01-01